Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: A multi-analytical approach

Molecular Diagnosis and Therapy

Volumn 17, Issue 6, 2013, Pages 371-379

  Tulsyan, Sonam ^a   Chaturvedi, Pankaj ^a   Agarwal, Gaurav ^a   Lal, Punita ^a   Agrawal, Sushma ^a   Mittal, Rama Devi ^a   Mittal, Balraj ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1;

ADULT; ANEMIA; ARTICLE; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; FEBRILE NEUTROPENIA; GENE INTERACTION; GENE LOCUS; GENE ORDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIFACTOR DIMENSIONALITY REDUCTION; NEUTROPENIA; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPISTASIS, GENETIC; FEMALE; GENETIC VARIATION; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PHARMACOGENETICS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TREATMENT OUTCOME;

EID: 84890481275     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0045-4     Document Type: Article

References (33)

1. Rodrigues FF, Santos RE, Melo MB, Silva MA, Oliveira AL, Rozenowicz RL, et al. Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res. 2008;7(1):177-83.
2. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, et al. Glutathione-S-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest. 2010;28(5):554-9.
3. Huang MY, Wang YH, Chen FM, Lee SC, Fang WY, Cheng TL, et al. Multiple genetic polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan. Ann Surg Oncol. 2008;15(3):872-80.
4. Hirshfield KM, Rebbeck TR, Levine AJ. Germline mutations and polymorphisms in the origins of cancers in women. J Oncol. 2010. 297671. doi: 10.1155/2010/297671.
5. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22(47):7369-75.
6. Armstrong RN. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol. 1997;10(1):2-18.
7. Zhong S, Huang M, Yang X, Liang L, Wang Y, Romkes M, et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol. 2006;62(4):457-72.
8. Perry RR, Mazetta JA, Levin M, Barranco SC. Glutathione levels and variability in breast tumors and normal tissue. Cancer. 1993;72(3):783-7.
9. Williams JA, Phillips DH. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res. 2000;60(17):4667-77.
10. Cho SG, Lee YH, Park HS, Ryoo K, Kang KW, Park J, et al. Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J Biol Chem. 2001;276(16):12749-55.
11. Chaturvedi P, Tulsyan S, Agarwal G, Lal P, Agarwal S, Mittal RD, et al. Influence of ABCB1 genetic variants in breast cancer treatment outcomes. Cancer Epidemiol. 2013. doi: 10.1016/j.canep.2013.04.012.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
14. Toruner GA, Akyerli C, Ucar A, Aki T, Atsu N, Ozen H, et al. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol. 2001;75(8):459-64.
15. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997;272(15):10004-12.
16. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med. 2002;21(1):35-50.
17. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003;19(3):376-82.
18. Ballet F, Robert J, Bouma ME, Vrignaud P, Infante R. Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture. Pharmacol Res Commun. 1986;18(4):343-7.
19. Camaggi CM, Strocchi E, Comparsi R, Testoni F, Angelelli B, Pannuti F. Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol. 1986;18(1):47-50.
20. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos. 1998;26(1):73-7.
21. Khedhaier A, Remadi S, Corbex M, Ahmed SB, Bouaouina N, Mestiri S, et al. Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br J Cancer. 2003;89(8):1502-7. doi: 10.1038/sj.bjc.66012926601292.
22. Mishra A, Chandra R, Mehrotra PK, Bajpai P, Agrawal D. Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. Surg Today. 2011;41(4):471-6. doi: 10.1007/s00595-009-4310-4.
23. Zhang BL, Sun T, Zhang BN, Zheng S, Lu N, Xu BH, et al. Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl). 2011;124(2):199-204.
24. Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer. 2005;103(1):52-8. doi: 10.1002/cncr.20729.
25. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, et al. Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010;16(24):6169-76. doi: 10.1158/1078-0432.CCR-10- 0281.
26. Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, Fargeot P, Brunet-Lecomte P. Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res. 1999;1(1):81-7. doi: 10.1186/bcr17.
27. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009;27(33):5519-28. doi: 10.1200/JCO.2008.21.6283.
28. Huang J, Tan PH, Thiyagarajan J, Bay BH. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol. 2003;16(6):558-65.
29. Harpole DH Jr, Moore MB, Herndon JE 2nd, Aloia T, D'Amico TA, Sporn T, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001;7(3):562-9.
30. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998;4(6):1469-74.
31. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y. Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res. 1999;25(6):387-94.
32. Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res. 1999;5(12):4097-104.
33. Hamajima N, Takezaki T, Tajima K. Allele frequencies of 25 polymorphisms pertaining to cancer risk for Japanese, Koreans and Chinese. Asian Pac J Cancer Prev. 2002;3(3):197-206.